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A multisystem disease is one that usually aﬀects a number of
organs and tissues during the course of the illness (Dorland,
2008). It has long been observed that some individuals with
schizophrenia have levels of general physical illnesses in
excess of that seen in the general population, but recent stud-
ies suggest that most people with schizophrenia have co-
morbid physical disease and multiple related risk factors.
Jones et al. (2004) reported that 74% of patients with schizo-
phrenia had at least one chronic co-morbid medical condi-
tion. Bell et al. (2009) found that 90% of Medicaid recipients
with schizophrenia had at least one major metabolic risk
factor. Using a higher standard of at least three major risk
factors (NCEP-ATP-III guidelines: abdominal obesity, hyper-
triglyceridemia, dyslipidemia, hypertension and hyperglyce-
mia) approximately 40% of European patients and up to
51.6% patients with schizophrenia in the United States satisfy
criteria for the metabolic syndrome (De Hert et al., 2009;
Meyer et al., 2005). In the METEOR study, the largest anal-
ysis of risk factors in schizophrenia and related disorders
reported that 69.9% had lipid disorders and 43.4% had
hypertension (De Hert et al., 2008). Together this evidence
suggests that most people with schizophrenia have a signiﬁ-
cant co-morbid physical illness and further the great majority
have metabolic risk factors (Mitchell and Malone, 2006).
Rates of co-morbidity appear to be inﬂuenced by the
severity of psychiatric symptoms, the setting of study and
nature of prescribed medication. Physical co-morbidity in
turn has an impact upon quality of life, suicide attempts
and mortality, even when suicide is eliminated (Heila et al.,
2005; Hennekens et al., 2005; Joukamaa et al., 2006; Kolotkin
et al., 2008). While core symptoms of schizophrenia usually
ﬁrst emerge in the late teens and early twenties, peripheral
physical disease gradually increases with age (Bresee et al.,
2010). Similarly metabolic risk factors are usually elevated
at ﬁrst episode but accumulate with time (Saddichha et al.,
2008). Lifestyle and cardiovascular risk factors play an
important role in the physical complications but they do
not appear to account for the entire variance (Connolly and
Kelly, 2005). Antipsychotic drugs certainly contribute to
physical co-morbidity (Oriot et al., 2008), but this eﬀect is
likelytobemagniﬁedinavulnerablepopulation.Allmetabolic
risk factors are important but we should give special attention
to those that are potentially reversible. Recent research has
highlighted some valuable insights in the following areas.
Body weight and lipids
Body weight, and in particular abdominal obesity, is a major
concern in schizophrenia and one that directly inﬂuences
quality of life (Kolotkin et al., 2008). A recent meta-analysis
suggested a typical weight gain of 3.8 kg in drug-naı¨ve
patients upon starting antipsychotic treatment (Tarricone
et al., 2010). Approximately 50% of those with schizophrenia
are overweight judging by waist circumference (De Hert et al.,
2009) and this ﬁgure may be around 20% in ﬁrst episode
patients (De Hert et al., 2006). The cardiovascular risk attrib-
utable to obesity and elevated levels of cholesterol, triglycer-
ides or low levels of high-density lipoproteins (HDLs) is well
recognized. Saari et al. (2005) examined serum lipids in
schizophrenia and related psychoses. Mean fasting total cho-
lesterol in patients with schizophrenia was 20 mg/dl higher
than in the healthy comparison group. In a controlled study
of drug-naı¨ve Chinese patients that used magnetic resonance
imaging, Zhang et al. (2004) found slight elevations in fat
indicators at baseline, but signiﬁcantly increased subcutane-
ous and intra-abdominal fat, following 10-week administra-
tion of chlorpromazine and risperidone. This is important
because visceral (intra-abdominal) adiposity is closely associ-
ated with hyperinsulinaemia, dyslipidaemia and impaired glu-
cose tolerance.
Glucose and insulin resistance
The link between schizophrenia and diabetes mellitus was
reported before the advent of antipsychotics (Braceland
et al., 1945; Kasanin, 1926; Lorenz, 1922). In approximately
half of the cases, hyperglycaemia resolves when the antipsy-
chotic drug is withdrawn and recurs if it is reintroduced
(Ananth et al., 2002). This would suggest that a large percent-
age of cases are drug-induced but many cases are not
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impaired glucose tolerance or insulin resistance is manifest in
ﬁrst episode drug-naı¨ve patients with schizophrenia (Ryan
et al., 2003; Cohn et al., 2006; Spelman et al., 2007;
Fernandez-Egea et al., 2009; Verma et al., 2009). However,
these problems accumulate especially in those taking atypical
antipsychotics (Gianfrancesco et al., 2006; Smith et al., 2008)
although this eﬀect is debated (Holt and Peveler, 2006).
Platelet activation
Walsh et al. (2002) found that drug-naı¨ve, ﬁrst-episode
schizophrenic patients had altered platelet function as evi-
denced by a signiﬁcantly increased number of integrin
aIIbbIIIa receptors/platelet. Such an increase might be
expected to indicate early platelet activation and to cause
increased platelet aggregation, thereby potentially contribut-
ing to the observed increased risk of development of cardio-
vascular disease in schizophrenic patients compared with the
general population.
Schizophrenia and inflammation
There is an evolving body of literature to support the view
that schizophrenia is a disorder with a pro-inﬂammatory phe-
notype, not just centrally but in the periphery also. Such a
view is consistent with the hypothesis that schizophrenia is a
multisystem disease and may help explain the high level of
physical co-morbidity. Postmortem brain studies have shown
activated microglial cells in at least a subset of patients with
schizophrenia (Radewiscz et al., 2000). There are also reports
of an increased frequency of activated lymphocytes in the
cerebrospinal ﬂuid (CSF) of patients with acute schizophrenia
(Nikkila ¨ et al., 1999).
Cytokines are key inﬂammatory messengers which may be
divided into a number of functional categories including
T-helper type 1 (Th1) and T-helper type 2 (Th2) groups. In
brief, Th1 cytokines are concerned with cell-mediated immu-
nity and Th2 cytokines with humoral immunity. Higher white
cell counts provide a crude inﬂammatory marker, an indirect
index of cytokine activity and are associated with an
increased risk for metabolic syndrome and more severe psy-
chopathology in non-diabetic patients with schizophrenia
(Fan et al., 2010). Several investigators have demonstrated
elevated interleukin (IL)-6 levels, a cytokine secreted by the
innate immune system and the Th2 arm of the adaptive
response, in the plasma of patients with schizophrenia.
Further evidence in support of Th2 arm activation derives
from studies reporting increased levels of IL-10 and IL-8 in
patients with schizophrenia. Overall, the data suggest a Th1/
Th2 imbalance. For a review see Stober et al. (2009) and
Potvin et al. (2008).
Conclusions
Schizophrenia is a disorder characterized by high rates of
physical co-morbidity and very high rates of metabolic risk
factors, many of which remain undiagnosed and untreated.
Physical co-morbidity often impacts upon quality of life and
ultimately mortality. We propose there is suﬃcient evidence
to consider schizophrenia a multisystem disease. We suggest
that reframing schizophrenia as a multisystem disease will
help focus the attention of mental health specialists and
non-mental health specialists on the physical needs of such
patients. Further work should attempt to clarify whether the
pro-inﬂammatory phenotype observed in schizophrenia is in
essence the basis of a multisystem disorder.
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